1492 Capital Management’s Pelthos Therapeutics PTHS Stock Holding History

1492 Capital Management’s Portfolio PTHS Stock Details PTHS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$293K	Buy	+10,380	New	+$266K	0.09%	114

Other funds holding PTHS

AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return

Murchinson Toronto, Ontario, Canada $725M AUM 82.02% 1-Year Est. Return

Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return

Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return

Vanguard Capital Management

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Cantor Fitzgerald New York $9.31B AUM 73.66% 1-Year Est. Return

J. Goldman & Co New York $3.87B AUM 46.92% 1-Year Est. Return

Diadema Partners Morristown, New Jersey $791M AUM 245.83% 1-Year Est. Return

Wexford Capital West Palm Beach, Florida $782M AUM 62.56% 1-Year Est. Return

David M. Knott Jr $189M AUM 67.72% 1-Year Est. Return

1492 Capital Management's PTHS Position: Q2 2026 in Review

1492 Capital Management opened a new position in Pelthos Therapeutics (PTHS) in Q2 2026: 10,380 shares worth $293K. The stake represents 0.09% of the portfolio and ranks #114 among its holdings.

24 funds tracked by Wall St. Rank hold PTHS as of Q2 2026.

1492 Capital Management held 10,380 shares of Pelthos Therapeutics worth $293K as of Q2 2026.
Pelthos Therapeutics was a new 1492 Capital Management position in Q2 2026.
Pelthos Therapeutics made up 0.09% of 1492 Capital Management's portfolio in Q2 2026, its #114 holding.
24 funds tracked by Wall St. Rank held Pelthos Therapeutics as of Q2 2026.

Based on 1492 Capital Management's 13F filing for Q2 2026, filed 11 Aug 2026.